Connect with us

Legal & Regulation

Presidential Candidate Bennet Urges Federal Financial Regulators to Clarify Hemp Banking Rules

Published

on

Presidential Candidate Bennet Urges Federal Financial Regulators to Clarify Hemp Banking Rules

Senator Michael Bennet (D-CO), a 2020 Democratic Presidential Candidate, is pressing federal regulators to issue updated guidance regarding hemp banking services.

Bennet wrote to the Federal Reserve Chairman Jerome Powell, acting CEO of Farm Credit Administration Jeffrey Hall, Treasury Comptroller Joseph Otting, Federal Deposit Insurance Corporation chairman Jelena McWilliams and the Chairman of the NCUA Rodney Hood saying that even though hemp and its derivatives were legalized under the 2018 farm bill, the crop’s farmers are still struggling to gain credit access.

Bennet touted the expanding market of hemp in his state and urged financial regulators to give guidelines on how financial institutions may provide financial services and products to hemp growers and processors.

In the letter, Bennet noted that hemp processing and cultivation is already supporting rural communities across the United States. However, he was uncomfortable that despite Colorado cultivating over 21,000 acres of hemp last year, farmers and processors still lack access to the banking system yet hemp is no longer classified as a schedule 1 drug.

Senator Bennet hoped that agencies could work expeditiously in a coordinated way to offer guidance that describes the manner in which financial institutions can provide financial products and services to hemp cultivators and processors. He feels that access to the banking system will provide certainty and clarity for the country’s hemp farmers and businesses. Bennet also feels that greater banking system access will make it easy for USDA to regulate hemp and conduct program oversight.

As lawmakers strive to pass legislation seeking to protect banks that serve cannabis businesses in legal states, hemp advocates in the Congress have clarified that they will keep on raising the issue of hemp financial services following the federal legalization of the crop.

Senator Jon Tester (D-MO) pushed a Federal Reserve’s top official to instruct banks to offer services to hemp businesses earlier this month during a Banking, Housing and Urban Affairs Committee of the Senate. This would elicit a pledge from a Federal Reserve official to make clear the bank’s situation

Mitch McConnell (R-KY), Senate Majority Leader, is set to introduce standalone bills that resolve glitches in the implementation of the measure. He promised to insert a language into disaster relief legislation to make sure that hemp farmers have federal crop insurance.

Denis is one of the most experienced researchers for reviews we have with years of experience in writing about CBD products. He will be one of the most viewed authors due to his own thrill in sharing what he is learning about cannabidiol and supplement use. With a goal of providing clarity within the budding CBD oil industry, Denis will be spending much of the year going through a catalogue of cannabis oil companies in the near future.

Continue Reading

Ultimate CBD Guide


Disclaimer

ultimate-cbd-products-company-guidepopular-cbd-health-benefits best-cannabidiol-guide-resources hemp guide

TimesofCBD is the most active daily CBD news publication featuring the latest cannabis industry stories and marijuana market trends. As the leader in CBD-centric content curation, we invite all readers to come for the headlines and stay for the insights. Quality is the top priority when presenting user guides, analyzing product reviews and reporting fact-checked news announcements. All information is for educational and informational purposes only. Disclaimer.

Got news? Email contact@timesofcbd.com

Copyright © 2020 TimesofCBD.com | Latest CBD News, Cannabis Guides and Marijuana Trends
Note: Always seek real additional medical advice and consultation with a professional healthcare practitioner before considering any CBD. No statements found on this website have underwent Food and Drug Administration evaluation. The efficacy of any products or claims made have never been approved by the FDA either. No products shall ever be intended to diagnose, treat or cure any disease or prevent any ailment.